Pcv118 - Factors Determining Selection of Appropriate Patients for Pcsk9 Inhibitors in European Clinical Practice

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.663
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Postgraduate Medicine
Medicine
2016English

Determining Appropriate Zones for Knowledge Intensive Firms Site Selection Using GIS

International Journal of Applied Geospatial Research
PlanningEarthPlanetary SciencesDevelopmentGeography
2019English

PCSK9 Peptide Inhibitors

Science-Business eXchange
2014English

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

PCSK9 Inhibitors: A Technology Worth Paying For?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2015English

Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

PCSK9 Inhibitors: When Statins Aren't Enough

Prescriber
Pharmacology
2017English

Angiogenic Factors in Preeclampsia: Implications for Clinical Practice

BJOG: An International Journal of Obstetrics and Gynaecology
GynecologyObstetrics
2018English

Appropriate Referral and Selection of Patients With Chronic Pain for Spinal Cord Stimulation: European Consensus Recommendations and E-Health Tool

European Journal of Pain
MedicineAnesthesiologyPain Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy